Emergence of Serogroup X Meningococcal Disease in Africa: Need for a Vaccine
This article, published in Vaccine, describes how and why serogroup X meningococcal disease has emerged in Africa in recent years. It asserts that while no licensed vaccine is available against serogroup X meningococci, following the introduction of a monovalent serogroup A conjugate vaccine (MenAfriVac®) in the meningitis belt and the upcoming introduction of pneumococcal conjugate vaccines, vaccine-based prevention of serogroup X may become a public health need. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Xie O, Pollard AJ, Mueller JE, Norheim G
Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Xie O, Pollard AJ, Mueller JE, Norheim G. Emergence of Serogroup X Meningococcal Disease in Africa: Need for a Vaccine. Vaccine. 2013;31(27):2852-2861.